Clinical use of serum prostate-specific antigen: a review.
Serum Prostate-Specific Antigen (PSA), in conjunction with digital rectal examination, is a common first-line clinical tool for the diagnosis of prostate cancer; therefore, it is essential that the clinical use of PSA be further developed to make it a more definitive tool. There are issues in screening with PSA, with regard to its lack of specificity (and sensitivity) and solutions involving various PSA parameters and derivatives have been suggested to address these issues. The literature on these parameters and research into factors found to influence levels of PSA are discussed in this review.
Gray
Marion A
MA
Department of Environmental and Infectious Disease Sciences, Division of Biophysical Toxicology, Armed Forces Institute of Pathology, Washington, DC 20306-6000, USA. marion.gray@afip.osd.mil
D006801:Humans; D008297:Male; D017430:Prostate-Specific Antigen / Q000097:blood*; D011471:Prostatic Neoplasms / Q000175:diagnosis*
D017430:Prostate-Specific Antigen